Sickle Cell Diseases Treatment Research Report, Share, and Forecast to 2025Posted by rekha on October 21st, 2019 Precision Business Insights (PBI) in its report titled “Global Sickle Cell Diseases Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over six years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. The global sickle cell diseases treatment market was valued at US$ 2.4 Bn in 2018 and growing at a CAGR of 12.6% over the forecast period owing to the rising occurrence of sickle cell anaemia in the developed, emerging as well as immature economies. In addition to this unmet needs are highly accessible, an upsurge in product pipelines for the treatment of SCD is predicted to posture high demand for the market. Sickle cell disease treatment market is boosted by increasing support by the regulatory frames and government in the form of investments, fast-track approvals for the discovery of newer treatments. However, slow adoption rate towards sickle cell disease treatment and lack of permanent cure for the disease restrains the growth of the market. Global sickle cell diseases treatment market segmented on the basis of disease type, therapy, drug class, end user, and region. Request for Sample Report @ https://www.precisionbusinessinsights.com/request-sample?product_id=16090
Blood transfusion segment accounted for higher revenue share Based on therapy, global sickle cell diseases treatment market segmented Bone Marrow Transplant, Blood Transfusion, and Gene Therapy. Blood transfusion segment is expected to grow with a significant growth over the forecast period. Current treatment for sickle cell disease is hydroxyurea and blood transfusions. High number of patient population developed intolerance to hydroxyurea. North America holds leading position in Global Sickle Cell Diseases Treatment Market PBI’s global sickle cell diseases treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America is expected to account for larger revenue share in 2018 and the same trend is projected to follow over 2019-2025 owing to the rise in research and development activities, high accessibility of established healthcare set-up and favorable reimbursement procedures are accrediting for the development of the SCD treatment market in the region. APAC and MEA regions are expected to grow with significant CAGR owing to increase in the prevalence of sickle cell anemia disease and increasing funding by the large number of market players in the region. Recent Developments in the Global Sickle Cell Diseases Treatment Market
Key player’s profiles in the report are Biogen (U.S.), Gamida Cell (Israel), Genetix Pharmaceuticals Inc. (U.S.), Sangamo Biosciences (U.S.), Alnylam Pharmaceuticals, Inc. (U.S.), Acceleron Pharma (U.S.), Global Blood Therapeutics Inc. (U.S.), Emmaus Medical, Inc. (U.S.), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (U.S.). Detailed Segmentation
By Disease Type o Sickle Beta Thalassemia o Sickle Haemoglobin C Disease o Sickle Cell Anaemia o Others By Therapy o Bone Marrow Transplant o Blood Transfusion o Gene Therapy
By Drug Class o Antibiotics o Analgesics o Antimetabolite (Hydroxyurea) o Others By End User o Hospitals o Retail Pharmacies o Others Geography
o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)
For more information: https://www.precisionbusinessinsights.com/market-reports/sickle-cell-diseases-treatment-market/ Like it? Share it! More by this author |